Syndax Pharmaceuticals reports Q3 2026 earnings with 82% revenue jump and narrowed loss
Syndax Pharmaceuticals announced its third‑quarter 2026 results on November 2. Total revenue surged 82% year‑over‑year to $83.30 million, driven by Revuforj net revenue of $60.74 million (up 90% YoY) and Niktimvo contribution of $22.55 million. The net loss narrowed to $49.43 million, or $0.55 per share, compared with $60.71 million a year earlier. The company also disclosed that CFO Keith Goldan will retire and be succeeded by Aaron Ondrey on November 9.
Why it matters
The revenue beat and loss narrowing improve Syndax’s cash‑flow outlook and support its FY 2026 expense guidance, according to the earnings release (12). Analysts note the stronger commercial traction of Revuforj and Niktimvo as a catalyst for future profitability (10, 11).
Key facts
- 1Total revenue for Q3 2026 was $83.30 million, up 82% from $45.87 million a year earlier. rttnews.com
- 2Net loss for the quarter was $49.43 million, or $0.55 per share, versus $60.71 million (or $0.70 per share) a year earlier. rttnews.com
- 3Revuforj net revenue was $60.74 million, a 90% increase year‑over‑year. rttnews.com
- 4Niktimvo contributed $22.55 million in collaboration revenue. rttnews.com
- 5GAAP EPS was –$0.55, missing consensus estimates by $0.04. seekingalpha.com
- 6The company maintained its FY 2026 combined R&D and SG&A expense guidance of approximately $400 million. rttnews.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.